Catabasis Pharmaceuticals, Inc. Gains 28.22%
Wed 02 Dec 20 at 05:32 PM
Catabasis Pharmaceuticals, Inc. (CATB:NASDAQ) rocketted at $2.09, a gain of 28.2%. On Tue 01 Dec 20, CATB:NASDAQ hit a New 2-Week Intraday High of $1.75. The stock got featured on our News Catalysts scanner on Thu 12 Nov 20 at 05:57 PM in the 'INVESTOR UPDATE' category. From Tue 17 Nov 20, the stock recorded 66.67% Up Days and 60.00% Green Days
The stock spiked on Mon 24 Aug 20 at $8.59 with a volume of 1M+, and its share price has been moving sideways in recent weeks.
About Catabasis Pharmaceuticals, Inc. (CATB:NASDAQ)
Catabasis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's primary focus is on treatments for rare diseases.
Top 10 Gainers:
- Merrimack Pharmaceuticals, Inc. (MACK:NASDAQ), 59.07%
- Tredegar Corporation (TG:NYSE), 29.86%
- Kingsway Financial Services Inc. (KFS:NYSE), 28.71%
- Cellectar Biosciences, Inc. (CLRB:NASDAQ), 28.71%
- Catabasis Pharmaceuticals, Inc. (CATB:NASDAQ), 28.22%
- FSTX (FSTX:NASDAQ), 27.63%
- Acorda Therapeutics, Inc. (ACOR:NASDAQ), 26.7%
- Sequential Brands Group, Inc. (SQBG:NASDAQ), 25.16%
- Natuzzi S.p.A. (NTZ:NYSE), 24.59%
- Sundial Growers Inc. (SNDL:NASDAQ), 23.83%